{"id":"comirnaty-biontech-manufacturing-gmbh","safety":{"commonSideEffects":[{"rate":"~70%","effect":"Injection site pain"},{"rate":"~60%","effect":"Fatigue"},{"rate":"~55%","effect":"Headache"},{"rate":"~40%","effect":"Myalgia"},{"rate":"~35%","effect":"Chills"},{"rate":"~15%","effect":"Fever"},{"rate":"~10%","effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains lipid nanoparticles encapsulating messenger RNA encoding the spike protein of SARS-CoV-2. Upon intramuscular injection, the mRNA is taken up by host cells, which translate it to produce spike protein. This protein is presented to the immune system, stimulating both CD8+ T-cell and antibody responses that protect against subsequent SARS-CoV-2 infection.","oneSentence":"COMIRNATY is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:06.243Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 6 months of age and older"},{"name":"Booster vaccination for COVID-19 in individuals 12 years of age and older"}]},"trialDetails":[{"nctId":"NCT06742281","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2024-12-05","conditions":"COVID-19","enrollment":432},{"nctId":"NCT04760132","phase":"PHASE4","title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)","status":"COMPLETED","sponsor":"Jens D Lundgren, MD","startDate":"2021-02-08","conditions":"SARS-CoV Infection","enrollment":7600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"COMIRNATY - BioNTech Manufacturing GmbH","genericName":"COMIRNATY - BioNTech Manufacturing GmbH","companyName":"Jens D Lundgren, MD","companyId":"jens-d-lundgren-md","modality":"Biologic","firstApprovalDate":"","aiSummary":"COMIRNATY is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection. Used for Prevention of COVID-19 in individuals 6 months of age and older, Booster vaccination for COVID-19 in individuals 12 years of age and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}